Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

Press/Media

Period3 Jun 2019

Media coverage

1

Media coverage

  • TitleSecondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
    Media name/outletPR Newswire
    Country/TerritoryUnited States
    Date3/06/19
    PersonsJoseph Sparano
View all 1
View less